<DOC>
	<DOCNO>NCT01546623</DOCNO>
	<brief_summary>The purpose study evaluate hormone dynamic , pharmacokinetics , safety , efficacy TAP-144-SR ( 6M ) TAP-144-SR ( 3M ) prostate cancer patient previously treat hormonal therapy .</brief_summary>
	<brief_title>A Phase 3 Comparative Study TAP-144-SR ( 6M ) Prostate Cancer Patients Previously Treated With Hormonal Therapy</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>1 . The participant histopathologically confirm prostate cancer Japanese . 2 . The participant prostate cancer clinical stage T1bT4 , Nany Many TNM classification clinical diagnosis time diagnosis . 3 . The participant ECOG performance status grade 0 , 1 , 2 screening . 4 . The participant PSA level increase 25 % great 2 ng/mL nadir measurement point 4 week longer apart within screen period 12 week . 5 . Patients receive market product 3 month ( LEUPLIN SR FOR INJECTION KIT 11.25 ) screen 6 . Patients receive marketed product , TAP144SR ( 1M ) TAP144SR ( 3M ) , 2496 week total schedule start date study drug , include administration period treat neoadjuvant therapy prostatectomy and/or radiation therapy 7 . Patients continue nonsteroidal antiandrogen longer 12 week schedule start date study drug , nonsteroidal antiandrogen concomitantly administer 8 . The participant serum testosterone level screen &lt; 100ng/dL 9 . The participant meet follow criterion renal , bonemarrow hepatic function laboratory test result screen : （1） Renal function : serum creatinine level &lt; 1.5 time upper limit normal ( ULN ) （2） Bonemarrow function : white blood count ≥ 3,500/ mm3 , platelet count ≥ 100,000/L , hemoglobin ≥ 10.0g/dL （3） Hepatic function : AST ( GOT ) , ALT ( GPT ) , ALP total bilirubin ≤ 2.5 time ULN 10 . The participant 's life expectancy least 24 month inform consent . 1 . The participant active multiple primary cancer , ( synchronous multiple primary cancer metachronous multiple primary cancer diseasefree survival ≤ 5 year ) 2 . The participant receive surgical castration . 3 . The participant ever receive LHRH agonist commercially available 1month 3month depot leuprolide acetate . 4 . The participant ever receive LHRH antagonist . 5 . Patients previously receive estrogen preparation corticosteroid prostate cancer 6 . Patients previously receive chemotherapy prostate cancer 7 . Patients receive receive marketed product 3 month ( LEUPLIN SR FOR INJECTION KIT 11.25 ) market product 1 month ( LEUPLIN FOR INJECTION 3.75 KIT 3.75 ) adjuvant therapy prostatectomy and/or radiotherapy 8 . Patients receive receive marketed product 3 month ( LEUPLIN SR FOR INJECTION KIT 11.25 ) intermittent androgen deprivation therapy 9 . Patients receive follow drug within 24 week ( 168 day ) start study drug : Steroidal antiandrogens , type II 5αreductase inhibitor 10 . The participant receive follow within 16 week ( 112 day ) prior study enrollment : （1） Radiotherapy . As I125 brachytherapy , within 35 week ( 245 day ) prior study enrollment . （2） Prostatectomy （3） Experimental therapy include highintensity focus ultrasound therapy ( HIFU ) , immunotherapy , gene therapy 11 . Patients receive follow drug within 4 week ( 28 day ) start study drug : Testosterones , ketoconazole（except external preparations） , spironolactone , corticosteroid ( exclude inhalant external preparation ) , Chinese medicine dietary supplement contain saw palmetto 12 . Patients whose QTcF interval exceed 460 msec 12lead electrocardiogram screen 13 . The participant history hypersensitivity synthetic LHRH , LHRH derivative component study drug . 14 . The participant central nervous system metastasis require treatment symptomatic . 15 . The participant already history complication may renal disorder cause spinal cord compression ureteric obstruction . 16 . The participant history serious drug allergic reaction/hypersensitivity 17 . The participant history , diagnose thromboembolism include myocardial infarction , cerebral infarction , venous thrombosis , pulmonary embolism , cardiac failure</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
</DOC>